Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery.
Neoadjuvant chemotherapy
Pancreatic ductal adenocarcinoma
R0 resection
Resectable
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
10
10
2022
accepted:
03
04
2023
medline:
7
7
2023
pubmed:
4
5
2023
entrez:
4
5
2023
Statut:
ppublish
Résumé
The efficacy of neoadjuvant chemotherapy with gemcitabine plus S-1 (NAC-GS) in the prognosis of patients with resectable pancreatic ductal adenocarcinoma (PDAC) has been reported. NAC-GS is now assumed to be a standard regimen for resectable PDAC in Japan. However, the reason for this improvement in prognosis remains unclear. In 2019, we introduced NAC-GS for resectable PDAC. From 2015 to 2021, 340 patients were diagnosed with resectable PDAC (anatomical and biological [carbohydrate antigen (CA) 19-9 < 500 U/mL]) and were divided according to the treatment period (upfront surgery [UPS] group, 2015-2019, n = 241; NAC-GS group, 2019-2021, n = 80). We used "intention-to-treat" analysis to compare the clinical outcomes of NAC-GS to those of UPS. Of the 80 patients with NAC-GS, 75 (93.8%) completed two cycles of NAC-GS, and the resection rate of the NAC-GS group was comparable to that of the UPS group (92.5 vs. 91.3%, P = 0.73). The R0 resection rate was significantly higher in the NAC-GS group than in the UPS group (91.3 vs. 82.6%, P = 0.04), even though the surgical burden was smaller. Progression-free survival tended to be better (hazard ratio [HR] = 0.70, P = 0.06), and overall survival was significantly better in the NAC-GS group than in the UPS group (HR 0.55, P = 0.02). NAC-GS provided improvements in microscopic invasion leading to a high R0 rate and smooth administration and completion of adjuvant therapy, which might lead to an improved prognosis in patients with resectable PDAC.
Sections du résumé
BACKGROUND
BACKGROUND
The efficacy of neoadjuvant chemotherapy with gemcitabine plus S-1 (NAC-GS) in the prognosis of patients with resectable pancreatic ductal adenocarcinoma (PDAC) has been reported. NAC-GS is now assumed to be a standard regimen for resectable PDAC in Japan. However, the reason for this improvement in prognosis remains unclear.
METHODS
METHODS
In 2019, we introduced NAC-GS for resectable PDAC. From 2015 to 2021, 340 patients were diagnosed with resectable PDAC (anatomical and biological [carbohydrate antigen (CA) 19-9 < 500 U/mL]) and were divided according to the treatment period (upfront surgery [UPS] group, 2015-2019, n = 241; NAC-GS group, 2019-2021, n = 80). We used "intention-to-treat" analysis to compare the clinical outcomes of NAC-GS to those of UPS.
RESULTS
RESULTS
Of the 80 patients with NAC-GS, 75 (93.8%) completed two cycles of NAC-GS, and the resection rate of the NAC-GS group was comparable to that of the UPS group (92.5 vs. 91.3%, P = 0.73). The R0 resection rate was significantly higher in the NAC-GS group than in the UPS group (91.3 vs. 82.6%, P = 0.04), even though the surgical burden was smaller. Progression-free survival tended to be better (hazard ratio [HR] = 0.70, P = 0.06), and overall survival was significantly better in the NAC-GS group than in the UPS group (HR 0.55, P = 0.02).
CONCLUSIONS
CONCLUSIONS
NAC-GS provided improvements in microscopic invasion leading to a high R0 rate and smooth administration and completion of adjuvant therapy, which might lead to an improved prognosis in patients with resectable PDAC.
Identifiants
pubmed: 37140750
doi: 10.1245/s10434-023-13534-z
pii: 10.1245/s10434-023-13534-z
doi:
Substances chimiques
Gemcitabine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5093-5102Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Motoi F, Kosuge T, Ueno H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019;49:190–4.
doi: 10.1093/jjco/hyy190
pubmed: 30608598
Inoue Y, Saiura A, Oba A, et al. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery. J Hepatobiliary Pancreat Sci. 2021;28:143–55.
doi: 10.1002/jhbp.844
pubmed: 33058515
Truty MJ, Kendrick ML, Nagorney DM, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg. 2021;273:341–9.
doi: 10.1097/SLA.0000000000003284
pubmed: 30946090
Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105:946–58.
doi: 10.1002/bjs.10870
pubmed: 29708592
pmcid: 6033157
Pijnappel EN, Suurmeijer JA, Koerkamp BG, et al. Consensus statement on mandatory measurements for pancreatic cancer trials for patients with resectable or borderline resectable disease (COMM-PACT-RB): a systematic review and Delphi Consensus Statement. JAMA Oncol. 2022;8:929–37.
doi: 10.1001/jamaoncol.2022.0168
pubmed: 35446336
Altman AM, Wirth K, Marmor S, et al. Completion of adjuvant chemotherapy after upfront surgical resection for pancreatic cancer is uncommon yet associated with improved survival. Ann Surg Oncol. 2019;26:4108–16.
doi: 10.1245/s10434-019-07602-6
pubmed: 31313044
DePeralta DK, Ogami T, Zhou JM, et al. Completion of adjuvant therapy in patients with resected pancreatic cancer. HPB (Oxford). 2020;22:241–8.
doi: 10.1016/j.hpb.2019.07.008
pubmed: 31563326
Javed AA, Floortje van Oosten A, Habib JR, et al. A delay in adjuvant therapy is associated with worse prognosis only in patients with transitional circulating tumor cells following resection of pancreatic ductal adenocarcinoma. Ann Surg. 2022.
Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049–57.
doi: 10.1016/S0140-6736(04)15841-8
pubmed: 15051286
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma (Version1.2020). 2019.
van Dam JL, Janssen QP, Besselink MG, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. Eur J Cancer. 2022;160:140–9.
doi: 10.1016/j.ejca.2021.10.023
pubmed: 34838371
Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40:1220–30.
doi: 10.1200/JCO.21.02233
pubmed: 35084987
Motoi F, Satoi S, Honda G, et al. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol. 2019;54:194–203.
doi: 10.1007/s00535-018-1506-7
pubmed: 30182219
Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2–11.
doi: 10.1016/j.pan.2017.11.011
pubmed: 29191513
JP. S. General rules for the study of pancreatic cancer, 7th edn. Kanehara & Co., Ltd; 2016.
Takeda T, Sasaki T, Mie T, et al. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. Jpn J Clin Oncol. 2021;51:604–11.
doi: 10.1093/jjco/hyaa247
pubmed: 33479765
Kuroki N, Ono Y, Sato T, et al. Long-term outcome of patients with postoperative refractory diarrhea after tailored nerve plexus dissection around the major visceral arteries during pancreatoduodenectomy for pancreatic cancer. World J Surg. 2022;46:1172–82.
doi: 10.1007/s00268-022-06457-5
pubmed: 35119513
Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.
doi: 10.1097/SLA.0b013e3181b13ca2
pubmed: 19638912
Inoue Y, Saiura A, Yoshioka R, et al. Pancreatoduodenectomy with systematic mesopancreas dissection using a supracolic anterior artery-first approach. Ann Surg. 2015;262:1092–101.
doi: 10.1097/SLA.0000000000001065
pubmed: 25587814
Inoue Y, Saiura A, Tanaka M, et al. Technical details of an anterior approach to the superior mesenteric artery during pancreaticoduodenectomy. J Gastrointest Surg. 2016;20:1769–77.
doi: 10.1007/s11605-016-3214-z
pubmed: 27456019
Inoue Y, Saiura A, Oba A, et al. Optimal extent of superior mesenteric artery dissection during pancreaticoduodenectomy for pancreatic cancer: Balancing surgical and oncological safety. J Gastrointest Surg. 2019;23:1373–83.
doi: 10.1007/s11605-018-3995-3
pubmed: 30306451
Watanabe G, Ito H, Sato T, et al. Left kidney mobilization technique during radical antegrade modular pancreatosplenectomy (RAMPS). Langenbecks Arch Surg. 2019;404:247–52.
doi: 10.1007/s00423-019-01767-0
pubmed: 30810806
Kato T, Inoue Y, Oba A, et al. Laparoscopic radical antegrade modular pancreatosplenectomy with anterocranial splenic artery-first approach for left-sided resectable pancreatic cancer (with videos). Ann Surg Oncol. 2022;29:3505–14.
doi: 10.1245/s10434-022-11382-x
pubmed: 35157192
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–9.
doi: 10.1001/archsurg.1992.01420110083017
pubmed: 1359851
Furukawa T, Sasaki T, Ono Y, et al. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Clin J Gastroenterol. 2021;14:1571–7.
doi: 10.1007/s12328-021-01480-w
pubmed: 34255287
Shaib Y, Davila J, Naumann C, et al. The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. population-based study. Am J Gastroenterol. 2007;102:1377–82.
doi: 10.1111/j.1572-0241.2007.01202.x
pubmed: 17403071
Shrikhande SV, Barreto SG. Surgery for pancreatic carcinoma: state of the art. Indian J Surg. 2012;74:79–86.
doi: 10.1007/s12262-011-0373-8
pubmed: 23372311
Bachellier P, Addeo P, Faitot F, et al. Pancreatectomy with arterial resection for pancreatic adenocarcinoma: how can it be done safely and with which outcomes? A single institution’s experience with 118 patients. Ann Surg. 2020;271:932–40.
doi: 10.1097/SLA.0000000000003010
pubmed: 30188399
Nagakawa Y, Yi SQ, Takishita C, et al. Precise anatomical resection based on structures of nerve and fibrous tissue around the superior mesenteric artery for mesopancreas dissection in pancreaticoduodenectomy for pancreatic cancer. J Hepatobiliary Pancreat Sci. 2020;27:342–51.
doi: 10.1002/jhbp.725
pubmed: 32048456
Sato T, Inoue Y, Takahashi Y, et al. Distal pancreatectomy with celiac axis resection combined with reconstruction of the left gastric artery. J Gastrointest Surg. 2017;21:910–7.
doi: 10.1007/s11605-017-3366-5
pubmed: 28116666
Chandrasegaram MD, Goldstein D, Simes J, et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg. 2015;102:1459–72.
doi: 10.1002/bjs.9892
pubmed: 26350029
Tanaka M, Inoue Y, Matsueda K, et al. Three-dimensional fixation: pathological protocol following pancreaticoduodenectomy with portal vein resection for pancreatic cancer. J Gastrointest Surg. 2020;24:619–26.
doi: 10.1007/s11605-019-04203-2
pubmed: 30937709